In May 2019, the U.S. Food and Drug Administration (FDA) sent a formal response to MAPS regarding the submitted protocol for an Expanded Access program for MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD).
In May 2019, the U.S. Food and Drug Administration (FDA) sent a formal response to MAPS regarding the submitted protocol for an Expanded Access program for MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD).